Can a blood test or Mini-Tumor predict immunotherapy success in lung cancer?

NCT ID NCT06405230

Recruiting now Knowledge-focused Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether special lab tools—like analyzing tiny particles from blood cells or growing mini-tumors in a dish—can predict how well immunotherapy drugs work in people whose lung cancer has returned. About 40 participants will receive standard immunotherapy drugs (pembrolizumab or dostarlimab) along with chemotherapy. The goal is to see if changes in these lab tests match what is seen on special PET scans, which could help doctors personalize treatment in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pembrolizumab and dostarlimab (immunotherapy drugs)
What this could lead to: If successful, this could lead to better ways to predict which lung cancer patients will benefit from immunotherapy, making treatment more personalized.
What could go wrong: This is a small, early-phase study focused on testing new measurement tools, not on proving the drugs work. The tools may not reliably predict outcomes in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER (NON-SMALL CELL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER (NON-SMALL CELL)

Contacts and locations

Locations

GSK Investigational Site
RECRUITING

London, SE1 9RT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.